Physician profile
Stuart P Childress, JR.
NPI 1558329342
$929.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $141.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $198.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.54 | 2019-2020 | |
| Novo Nordisk INC | $90.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $85.67 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $75.08 | 2019 | |
| Lilly USA, LLC | $67.99 | 2019-2020 | |
| Mylan Specialty L.P. | $53.31 | 2019-2020 | |
| United Therapeutics Corporation | $37.30 | 2019 | |
| Shire North American Group INC | $29.64 | 2019 | |
| Grifols USA, LLC | $28.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.72 | 2019 | |
| Philips North America LLC | $24.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.71 | 2019 | |
| Genentech USA, INC. | $20.15 | 2019 | |
| Gilead Sciences, INC. | $17.91 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.12 | 2019 | |
| Tactile Systems Technology INC | $13.18 | 2019 | |
| Pfizer INC. | $12.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Childress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.